This is a working overview of Thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-11. Anything still debated is marked as such rather than presented as settled.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
2020, A. T. Williams, C. R. Muller, A. M. Eaker, D. A. Belcher, C. Bolden-Rush, A. F. Palmer, P. Cabrales, “Polymerized hemoglobin with increased molecular size reduces toxicity in healthy guinea pigs,” ACS Applied Bio Materials Apr 14 3, 5:2976–2985. 2020, A. T. Williams, A. Lucas, C. R. Muller, C. Bolden-Rush, A. F. Palmer, P. Cabrales, “Balance between oxygen transport and blood rheology during resuscitation from hemorrhagic shock with polymerized hemoglobin,” Journal of Applied Physiology Jul 1;129(1):97-107. 2021, C. R. Muller, A. Lucas, V. Courelli, A. T. Williams, F. Dos Santos, C. Cuddington, S. Moses, A. F. Palmer, E. Kistler, P. Cabrales, “Resuscitation from hemorrhagic shock after traumatic brain injury with polymerized hemoglobin,” Scientific Reports Jan 28;11(1):2509. Facilitated oxygen transport Palmer's research focuses on approaches to better improve oxygen storage and transport to cultured cells, especially cells grown in bioreactors. Supporting Publications:
Almost every incumbent party worldwide facing election in 2024 lost vote share, including in South Africa, India, France, the United Kingdom, and Japan. Among democracies, over 80 percent saw the incumbent party lose support compared to the last election. This is the first time this has ever happened since 1905 (when data was first recorded) and the first time in the history of democracy, as universal suffrage began in 1894. All 50 states and the District of Columbia shifted rightward compared to 2020. Trump's gains in nearly all geographic areas and among nearly every demographic group provides strong evidence of anti-incumbent backlash. The shifts toward Trump were much less in the swing states where both campaigns focused compared to safe states. The two states with the largest shifts toward Trump, New York and New Jersey, were both won by Harris. Harris had very little room to fall in the swing states, given that Biden had won most of them by very small margins in 2020. Statistician and election analyst Nate Silver argued before the election that the national electoral environment was difficult for Democrats. This view was also shared by The New York Times political analyst Nate Cohn. After the election, Silver felt that Harris was a replacement-level candidate who did much better than Biden would have, but was unable to separate herself from Biden's record and was negatively perceived by swing voters due to her previous positions.
=== EC 1.23.1 With NADH or NADPH as donor === EC 1.23.1.1: (+)-Pinoresinol reductasa EC 1.23.1.2: (+)-lariciresinol reductase EC 1.23.1.3: (–)-pinoresinol reductase EC 1.23.1.4: (–)-lariciresinol reductase
== Structure == Serous membranes have two layers. The parietal layers of the membranes line the walls of the body cavity (pariet- refers to a cavity wall). The visceral layer of the membrane covers the organs (the viscera). Between the parietal and visceral layers is a very thin, fluid-filled serous space, or cavity.
Marie Maynard Daly (April 16, 1921 – October 28, 2003) was an American biochemist. She was the first African-American to receive a Ph.D. from Columbia University and the first African-American woman in the United States to earn a Ph.D. in chemistry. Daly made important contributions in four areas of research: the chemistry of histones, protein synthesis, the relationships between cholesterol and hypertension, and creatine's uptake by muscle cells.
Sources: en.wikipedia.org
== External links == Imidazoline+Receptors at the U.S. National Library of Medicine Medical Subject Headings (MeSH) imidazoline receptor 2 at the U.S. National Library of Medicine Medical Subject Headings (MeSH) imidazoline I1 receptors at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
== History == The use of snail slime in cosmetics and pharmaceutical applications dates back to ancient Greece, where it was recommended as a treatment for skin inflammation. Early practices involved crushing secretions from brown garden snails to help alleviate inflammatory skin conditions. This approach is part of a broader tradition known as zootherapy, which has existed since ancient Mesopotamia and Egypt and involves the use of animal-based remedies for healing. Additionally, snails were known to be high in nutrients and as a delicacy to be eaten.
Plaid Cymru expels Senedd member Rhys ab Owen after he was found to have inappropriately touched and sworn at two women while drunk at a party. Former Chancellor Nadhim Zahawi, who stood down from Parliament at the general election, is reported to be seeking financial backers in order to bid for the Daily Telegraph and The Spectator. 23 July – Seven Labour MPs, including former shadow chancellor John McDonnell and former shadow minister Rebecca Long-Bailey, have the Labour whip suspended for six months after voting against the government and in favour of an SNP amendment to scrap the two-child benefit cap. McDonnel said, "I'm following Keir Starmer's example as he said put country before party". The Home Office confirms that contract for the Bibby Stockholm, the vessel used to house asylum seekers, will not be renewed after January 2025. Documents released by The National Archives reveal that former prime minister Harold Wilson agreed to sell his private papers late in life in order to provide funds for his care. A deal agreed with Canada's McMaster University in 1990 attracted concern from the Cabinet Office because documents relating to his time in office remained private under the thirty year rule, which would not apply if they went to Canada. They were eventually sold to Oxford's Bodleian Library. 2024 Conservative Party leadership election: James Cleverly, who served as home secretary and foreign secretary in the Sunak government, announces his intention to run for the post of Conservative Party leader. 24 July – Starmer attends his first PMQs as prime minister.
Polonium has few applications, and those are related to its radioactivity: heaters in space probes, antistatic devices, sources of neutrons and alpha particles, and poison (e.g., poisoning of Alexander Litvinenko). It is extremely dangerous to humans.
Some molecular biology research suggests that GAHT induces a "unique molecular profile" with potential relevance to the recipient's immune system, or (in)susceptibility to certain health conditions (which are sometimes sexually dimorphic in people); one 2022 analysis found that GAHT (both feminizing and masculinizing) influenced gene expression. The study's lead author stated that they observed "changes [to] the epigenetic landscape of DNA" in some regions but not others, and that of the observed "epigenetic changes in regions of DNA that were distinct between sexes before hormone therapy, these regions consistently shifted towards the profile of the affirmed gender after 12 months of hormone therapy." A 2023 molecular study on the breast tissue of transgender men found that adding androgens induced such changes, appearing to silence genes across the breast tissue, including a suppression of genes linked to breast cancer.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.